National Pension Service raised its holdings in shares of Pfizer (NYSE:PFE) by 2.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,638,217 shares of the biopharmaceutical company’s stock after acquiring an additional 104,546 shares during the quarter. Pfizer makes up about 0.8% of National Pension Service’s investment portfolio, making the stock its 23rd biggest position. National Pension Service owned about 0.08% of Pfizer worth $167,996,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Mckinley Capital Management LLC Delaware purchased a new position in shares of Pfizer during the second quarter valued at approximately $103,000. Herndon Capital Management LLC purchased a new position in shares of Pfizer during the second quarter valued at approximately $120,000. Americafirst Capital Management LLC purchased a new position in shares of Pfizer during the third quarter valued at approximately $127,000. Oak Point Wealth Management purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $165,000. Finally, Lipe & Dalton boosted its position in shares of Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 300 shares during the period. 71.20% of the stock is currently owned by institutional investors and hedge funds.
PFE has been the subject of a number of research reports. Sanford C. Bernstein set a $43.00 price target on Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a report on Wednesday, January 17th. Morgan Stanley set a $41.00 price target on Pfizer and gave the company a “buy” rating in a report on Friday, January 5th. JPMorgan Chase reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, January 30th. Finally, BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday, December 8th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $39.25.
In other news, EVP Rady A. Johnson sold 27,323 shares of the stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $36.55, for a total transaction of $998,655.65. Following the sale, the executive vice president now directly owns 70,332 shares of the company’s stock, valued at approximately $2,570,634.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Charles H. Hill sold 42,393 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total transaction of $1,515,973.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 248,037 shares of company stock worth $9,064,785. Corporate insiders own 0.06% of the company’s stock.
NYSE:PFE traded down $0.56 during mid-day trading on Friday, hitting $35.17. The company’s stock had a trading volume of 21,146,274 shares, compared to its average volume of 22,138,338. Pfizer has a 1 year low of $31.67 and a 1 year high of $39.43. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. The firm has a market cap of $212,695.86, a price-to-earnings ratio of 13.27, a PEG ratio of 1.78 and a beta of 0.90.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. During the same period in the prior year, the company earned $0.47 earnings per share. The firm’s revenue was up .6% on a year-over-year basis. equities research analysts predict that Pfizer will post 2.96 earnings per share for the current fiscal year.
Pfizer declared that its Board of Directors has authorized a share buyback plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
WARNING: “Pfizer (PFE) Shares Bought by National Pension Service” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/pfizer-inc-pfe-stake-boosted-by-national-pension-service.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.